Greatmark Investment Partners’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-19,601
| Closed | -$194K | – | 140 |
|
|
2021
Q2 | $194K | Sell |
19,601
-156,140
| -89% | -$1.65M | 0.04% | 134 |
|
|
2021
Q1 | $2.03M | Buy |
175,741
+102,205
| +139% | +$1.17M | 0.4% | 51 |
|
|
2020
Q4 | $710K | Sell |
73,536
-28,210
| -28% | -$270K | 0.15% | 68 |
|
|
2020
Q3 | $917K | Sell |
101,746
-22,728
| -18% | -$240K | 0.23% | 60 |
|
|
2020
Q2 | $1.53M | Sell |
124,474
-1,660
| -1% | -$18.8K | 0.4% | 49 |
|
|
2020
Q1 | $1.13M | Sell |
126,134
-400
| -0.3% | -$4.1K | 0.36% | 51 |
|
|
2019
Q4 | $1.24M | Sell |
126,534
-4,364
| -3% | -$39K | 0.31% | 55 |
|
|
2019
Q3 | $901K | Sell |
130,898
-11,290
| -8% | -$86.5K | 0.25% | 61 |
|
|
2019
Q2 | $1.31M | Buy |
142,188
+17,728
| +14% | +$214K | 0.39% | 50 |
|
|
2019
Q1 | $1.95M | Sell |
124,460
-5,475
| -4% | -$96.6K | 0.62% | 41 |
|
|
2018
Q4 | $2M | Sell |
129,935
-118,025
| -48% | -$2.42M | 0.72% | 37 |
|
|
2018
Q3 | $5.34M | Buy |
247,960
+1,575
| +0.6% | +$36.6K | 1.68% | 22 |
|
|
2018
Q2 | $5.99M | Sell |
246,385
-6,596
| -3% | -$135K | 2.07% | 19 |
|
|
2018
Q1 | $4.32M | Sell |
252,981
-9,594
| -4% | -$187K | 1.58% | 21 |
|
|
2017
Q4 | $4.98M | Sell |
262,575
-61,759
| -19% | -$929K | 1.8% | 20 |
|
|
2017
Q3 | $5.71M | Buy |
324,334
+153,050
| +89% | +$3.44M | 2.18% | 17 |
|
|
2017
Q2 | $5.69M | Buy |
171,284
+22,963
| +15% | +$711K | 2.28% | 15 |
|
|
2017
Q1 | $4.76M | Buy |
148,321
+21,060
| +17% | +$719K | 1.96% | 18 |
|
|
2016
Q4 | $4.61M | Buy |
127,261
+1,783
| +1% | +$71.2K | 1.94% | 18 |
|
|
2016
Q3 | $5.77M | Buy |
125,478
+495
| +0.4% | +$25.8K | 2.51% | 15 |
|
|
2016
Q2 | $6.28M | Buy |
124,983
+352
| +0.3% | +$18.7K | 2.8% | 12 |
|
|
2016
Q1 | $6.67M | Buy |
124,631
+11,110
| +10% | +$652K | 3.02% | 11 |
|
|
2015
Q4 | $7.45M | Buy |
113,521
+1,300
| +1% | +$80.3K | 3.27% | 10 |
|
|
2015
Q3 | $6.34M | Sell |
112,221
-3,364
| -3% | -$218K | 2.93% | 12 |
|
|
2015
Q2 | $6.83M | Buy |
115,585
+450
| +0.4% | +$27.8K | 2.92% | 13 |
|
|
2015
Q1 | $7.17M | Buy |
115,135
+1,850
| +2% | +$108K | 3.08% | 12 |
|
|
2014
Q4 | $6.51M | Buy |
113,285
+2,095
| +2% | +$117K | 2.79% | 12 |
|
|
2014
Q3 | $5.98M | Sell |
111,190
-975
| -0.9% | -$51.7K | 2.77% | 11 |
|
|
2014
Q2 | $5.88M | Buy |
112,165
+1,870
| +2% | +$95.6K | 2.46% | 12 |
|
|
2014
Q1 | $5.83M | Buy |
110,295
+4,760
| +5% | +$220K | 2.6% | 10 |
|
|
2013
Q4 | $4.23M | Buy |
105,535
+6,040
| +6% | +$238K | 2% | 16 |
|
|
2013
Q3 | $3.76M | Buy |
99,495
+5,900
| +6% | +$230K | 1.96% | 16 |
|
|
2013
Q2 | $3.67M | Buy |
+93,595
| New | +$3.64M | 2.36% | 12 |
|
Other funds holding TEVA
ACM
MIFH
MMH
CI
PF
Greatmark Investment Partners's TEVA Position: Q3 2021 in Review
Greatmark Investment Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2021, closing a stake of 19,601 shares — an estimated $194K sold.
Greatmark Investment Partners first reported a position in TEVA in Q2 2013 and held it in 33 quarters. The position peaked at $7.45M in Q4 2015. 429 funds tracked by Wall St. Rank hold TEVA as of Q3 2021.
- Greatmark Investment Partners reported no remaining Teva Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
- Greatmark Investment Partners sold 19,601 Teva Pharmaceuticals shares in Q3 2021, an estimated $194K.
- Greatmark Investment Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 33 quarters.
- Greatmark Investment Partners's Teva Pharmaceuticals position peaked at $7.45M in Q4 2015.
- 429 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2021.
Based on Greatmark Investment Partners's 13F filing for Q3 2021, filed 2 Nov 2021.